CA1069394A - Antimicrobial sutures - Google Patents
Antimicrobial suturesInfo
- Publication number
- CA1069394A CA1069394A CA238,786A CA238786A CA1069394A CA 1069394 A CA1069394 A CA 1069394A CA 238786 A CA238786 A CA 238786A CA 1069394 A CA1069394 A CA 1069394A
- Authority
- CA
- Canada
- Prior art keywords
- suture
- surgical aid
- heparin
- surgical
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 41
- 229920000669 heparin Polymers 0.000 claims abstract description 52
- 229960002897 heparin Drugs 0.000 claims abstract description 49
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000004599 antimicrobial Substances 0.000 claims abstract description 22
- 229920002635 polyurethane Polymers 0.000 claims abstract description 14
- 239000004814 polyurethane Substances 0.000 claims abstract description 14
- 239000004744 fabric Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 229920001971 elastomer Polymers 0.000 claims description 17
- 239000000806 elastomer Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 16
- 229920006318 anionic polymer Polymers 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000000129 anionic group Chemical group 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 8
- 229920001296 polysiloxane Polymers 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000004952 Polyamide Substances 0.000 claims description 7
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229920002647 polyamide Polymers 0.000 claims description 7
- 229920000570 polyether Polymers 0.000 claims description 7
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 6
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229940053050 neomycin sulfate Drugs 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229960002796 polystyrene sulfonate Drugs 0.000 claims description 5
- 239000011970 polystyrene sulfonate Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 229930182566 Gentamicin Natural products 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229960002385 streptomycin sulfate Drugs 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 2
- 229960003866 cefaloridine Drugs 0.000 claims description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims 4
- 229940070721 polyacrylate Drugs 0.000 claims 2
- YVSHCKXUFJPXCX-ZWOKJYBLSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2s,5r,6r)-3,3-dimethyl-7- Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O YVSHCKXUFJPXCX-ZWOKJYBLSA-N 0.000 claims 1
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 claims 1
- VDUVBBMAXXHEQP-SLINCCQESA-M oxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-SLINCCQESA-M 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 1
- 229940083555 sodium cephalothin Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 229940074731 ophthalmologic surgical aids Drugs 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 230000005923 long-lasting effect Effects 0.000 abstract description 3
- 229920001198 elastomeric copolymer Polymers 0.000 abstract description 2
- 229920000447 polyanionic polymer Polymers 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000012153 distilled water Substances 0.000 description 24
- -1 polypropylene Polymers 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000005442 diisocyanate group Chemical group 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003356 suture material Substances 0.000 description 4
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 3
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920003225 polyurethane elastomer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001974 tryptic soy broth Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229920001228 polyisocyanate Polymers 0.000 description 2
- 239000005056 polyisocyanate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- GUEIZVNYDFNHJU-UHFFFAOYSA-N quinizarin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=CC=C2O GUEIZVNYDFNHJU-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 description 1
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- SBJCUZQNHOLYMD-UHFFFAOYSA-N 1,5-Naphthalene diisocyanate Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1N=C=O SBJCUZQNHOLYMD-UHFFFAOYSA-N 0.000 description 1
- WOMTYMDHLQTCHY-UHFFFAOYSA-N 3-methylamino-1,2-propanediol Chemical compound CNCC(O)CO WOMTYMDHLQTCHY-UHFFFAOYSA-N 0.000 description 1
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- WCIJNGGYNIHSTJ-UHFFFAOYSA-N CCOC(NO)=O.N=C=O Chemical compound CCOC(NO)=O.N=C=O WCIJNGGYNIHSTJ-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N Haematein Natural products C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 229920002121 Hydroxyl-terminated polybutadiene Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000002251 absorbable suture material Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- HNNSUZPWERIYIL-UHFFFAOYSA-N chembl1730100 Chemical compound O1CC2(O)CC3=CC(O)=C(O)C=C3C2=C2C1=C(O)C(=O)C=C2 HNNSUZPWERIYIL-UHFFFAOYSA-N 0.000 description 1
- SXYCCJAPZKHOLS-UHFFFAOYSA-N chembl2008674 Chemical compound [O-][N+](=O)C1=CC=C2C(N=NC3=C4C=CC=CC4=CC=C3O)=C(O)C=C(S(O)(=O)=O)C2=C1 SXYCCJAPZKHOLS-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- IZKZIDXHCDIZKY-UHFFFAOYSA-N heptane-1,1-diamine Chemical compound CCCCCCC(N)N IZKZIDXHCDIZKY-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003692 nonabsorbable suture material Substances 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940006297 other ophthalmologic surgical aid in atc Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930183279 tetramycin Natural products 0.000 description 1
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
ABSTRACT
A surgical suture is coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer such as heparin.
The coated suture is receptive to treatment with anti-microbial compounds to produce a suture having long-lasting antimicrobial properties which inhibit bacterial growth in and immediately around the suture. The coated suture is also receptive to dyes for the preparation of colored sutures. Surgical aids other than sutures such as films, fabrics, wound dressings and the like may be coated and rendered antimicrobial or colored in a like manner.
A surgical suture is coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer such as heparin.
The coated suture is receptive to treatment with anti-microbial compounds to produce a suture having long-lasting antimicrobial properties which inhibit bacterial growth in and immediately around the suture. The coated suture is also receptive to dyes for the preparation of colored sutures. Surgical aids other than sutures such as films, fabrics, wound dressings and the like may be coated and rendered antimicrobial or colored in a like manner.
Description
~ii939~
; The present invention relates to antimicrobial surgical aids, particularly sutures, that have present on the surface thereof a polymer coating, particularly on antimicrobial composi-tion that is not readily removed from the suture by leaching with water.
Germicidal sutures are described in the U.S. Patents No. 8~1,231, 1,741,893, and 2,751,910 and more recently in patents that have issued to Dr. Leonard D. Kurtz, i.e., U.S.
Patent No. 3,~42,003. South African Patent No. 724,131 describes a suture having long-lasting germicidal properties against both gram-negative and gram-positive bacteria due to the presence with-in the suture of an insoluble salt of a cation of a basic anti-biotic and an anion of an acid antibiotic, i.e., gentamycin oxa-cillinate. It is stated that such sutures, after being placed in mice for five days show no growth of organisms when removed and placed in a culture medium.
~, The Kliment et al British Patent 1,248,513 and the , Shepherd U.S. Patent 3,632,416 and U.S. 3,674,901 describe coated sutures that will accept medicinal agents. But, it is a disad-vantage of the suture coatings described that they have in~erior mechanical properties and are easily removed from the suture.
The suture of the present invention offers an advantage over those described in South African Patent No. 724,131 in that any anionic or cationic antimicrobial may be incorporated in the suture, and the incorporation may take place at the time of manufacture or at the time of use. Once incorporated in the suture, the antimicrobial will be retained by the suture strand over extended periods of use. Water, blood and tissue fluids slowly leach the antimicrobial compound out of the suture over a prolonged period of time.
The sutures of the present invention are any convention-al multifilament or monofilament suture material including for .
~0~39~
.
example, polyester, polypropylene, silk, cotton and linen which is coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer such as heparin. The coated suture is receptive to treatment with anionic or cationic antimicrobial compounds and/or anionic or cationic dyes. The antimicrobial treated suture is resis~ent to leaching and retains its antimicrobial properties in the pres-; ence of water or tissue fluid for a significant period of time to inhibit bacterial growth in and around the suture. The dyed sutures are useful for quick identification in surgical proce-dures where multiple sutures are employed.
The invention relates to an antimicrobial surgical aid the surface of which is coated with ~n ionic block elastomer of the formula:
Z - - Rl - ZY - R _y 12 ...x _ 3 4 R5 _ n wherein R is Cl-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, Rl is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y, n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic antimicrobial compound.
The preferred antimicrobial surgical aids of the pres-ent invention are suture strands coated with high-heparin content polyquaternary polyurethane elastomer and then treated with selected antimicrobials. The bonding of heparin to polymers has been reported by Yen & Rembaum, J. Biomed. Mater, Res. Symposium, Vol. 1 pp 83-97 (1971). Block copolymers of poly-quaternary ~ ;9394 polyure~hane and heparin containing from 5 to 20 percent of he-parin are described and claimed in U.S. Patent 3,755,218 where such copolymers are disclosed as having non-thrombogenic charac-teristics and suggested for use in coating surgical devices such as membranes, tubes, catheters, valves, prosethetic veins and the like where blood clotting is of g-eat concern. I have now found that these high-heparin content polyquaternary polyurethare elastomers are a useful substrate for retaining and slowly releasing selected antimicrobial compounds. While any of a variety of surgical aids may be rendered antimicrobial by the method of the present invention, the treatment of sutures is a particularly preferred embodiment of the present invention and the ensuing description will accordingly be directed primarily to sutures.
A preferred ionically bonded block elastomeric copo-lymer that functions as the coating material and the substrate for the antimicrobial compound or dye group in the present in ;~
vention is described in U.S. Patent 3,755,218. The copolymer formed between heparin and a polyquaternary polyurethane may be represented by the formula:
~ Z '----Rl--ZY~R ~ Y ~ .
R12 (I) ;~
/ ~ \ B-_ R3 R4 R5 n where R is Cl-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, Rl is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups and ZY is the urethane residue of the condensation of Z
and Y; n is an integer from 10 to 1,000; and B- is heparin. As used herein, lower~alkyl and alkylene radicals are those con-,. . -: ~
~1069394 taining from 1 to about ~ carbon atoms, and preferably from 1 to 4 carbon atoms.
The general reaction synthesis for the preparation of the polyquaternary polyurethane comprises reaction of a compound of the formula:
z-Rl-Z (II) or Z-Rl-Y (III) with a compound of the formula:
Y-R-Y or Z-RI-Y
12 (IV) lR2 (V) R3-N-R4 R3-~-R3 to form an intermediate non-charged or neutral poly-tertiary amino polymer of the formula:
_ _ z _--Rl--ZY-R ---_ y . IR2 (VI) R3 -N-R4 n where R, Rl, R2, R3 and R4 and n have the above-defined meanings.
The polymer is then reacted with a quaternizing reagent of the formula:
where A is an anion, suitably halo, to form a polymer having the structure:
Z- ~Rl--ZY--R ----y R2 (vII) N+ A-. _ 3 R4 R.5 _ n The materials for the monomeric materials of Formula I
and Formula II are preferably liquids of prepolymer length having a molecular weight above about 400 and below the range at which the prepolymer becomes excessively viscous or solid, suitably _ ~ _ 'I ~)fà9394 below 6,000 and preferably l,000 to 3,000. The group Rl may be an aromatic or aliphatic hydrocarbon, either saturated or un-saturated or may be a polyether, silicone (e.g., a siloxane), polyamide, polyurethane or other type of prepolymer.
The Z and Y groups are selected from condensation coreactants generally utilized in forming condensation resins such as isocyanate-hydroxyl (urethane) isocyanate-amine (urea), hydroxyl-carboxyl (polyester) amino-carboxyl (amide) and the like. Urethane linking reactants are preferred due to the ready availability of diverse polyisocyanate materials, the absence of elimination products and the ready ability to select and con- ;
trol the properties of the final prepolymer.
Examples of suitable monomeric diisocyanates include benzene-1,3-diisocyanate, hexane-1,6-diisocyanate, tolylene-2,4-diisocyanate (TDI), tolylene-2,3-diisocyanate, diphenylmethane-` 4,4-diisocyanate, naphthalene-1,5-diisocyanate, diphenyl 3,3'-dimethyl-4,4'-diisocyanate, diphenyl-3,3'-dimethoxy-4,4'-diiso-cyanate diethyl etner, 3 (diethylamino) pentane-1,5-diisocyanate, butane-l,4-diisocyanate, cyclohex-4-ene-1,2-diisocyanate, tolui-dine diisocyanate, isocyanate terminated prepolymers, polyaryl diisocyanates, and the like. Suitable commercially available higher molecu~ar weight liquid polyisocyanates are Adiprene L-lO0 (Trademark of DuPont), an isocyanate terminated polybutyl-ene oxide having a molecular weight of about 2,000 and Adiprene L-167 (Trademark of DuPont), an isocyanate terminated polybutyl-ene oxide having a molecular weight of about 1,350.
Terminally reactive liquid polymers, such as hydroxy terminated polybutadienes containing 20 to 500 or more carbon atoms or Bis-phenol A terminated liquid polysiloxanes can be converted to diisocyanates by reaction with a diisocyanate such as hexa-methylene diisocyanate. As the carbon chain length of the prepolymer increases, elastomeric properties are favored.
10~;939~
The Rl group in the monomeric compounds of Formulas III and IV may be aliphatic, aromatic or the various prepolymers discussed above. In the case of the use of a prepolymer diiso-cyanate the hydroxy amine material is suitably a compound of ; the formula:
OH(CH ) CH(CH ) (C12)m where R6 and R7 are lower alkyl, aryl such as phenyl, aralkyl such as benzyl or lower alkenyl, and each m is individually an integer from 0 to about 6 and m' is an integer of from 1 to about 6. Exemplary compounds are 3-dimethylamino-1,2,-propane diol, 4-diethylamino-1,3-butane diol 5-dimethylamino-1,4-hexane diol.
In the ~uaternizing reagent R5A, R5 may be hydrogen or lower alkyl, and A may be halo such as chloro, bromo or iodo, alkyl sulfate such as methyl sulfate, or alkyl iodide such as methyl iodide.
The polymerization reaction may be conducted in bulk or in the presenceof a solvent for the monomers and polymer pro-duct such as benzene. The reaction may be conducted at room temperature or at elevated temperature up to or above the reflux temperature. The quaternization reaction is conducted in the presence of a solventfor the tertiary amino polymer and for the resulting quaternary salt such as tetrahydrofuran, acetone, dioxane, dimethylformamide, diaminoheptane, or mixtures thereof.
The quaternized elastomeric polymer are further reacted with anionic polymers or salts thereof such as polystyrene sul-fonate, polyacrylates and the like and particularly with heparin or its alkali metal or ammonium salts to form viscoelastic ionically linked block polymeric salts of the formula:
1~939~
Z ~ R -ZY - R ~ Y
L R3 R~ R5 ~
wherein B- is an anionic polymer, preferably heparin, and R - R5, Z, Y and n are as defined above.
The heparin content æ the block polymer can be varied between 5% to about 20% by weight. Higher heparin content - materials can be prepared but are found to have a lower degree of elasticity. Lower heparin content materials are soluble in common organic solvents while materials containing above 15% - -; heparin are soluble in polar solvents such as THF, dimethylfor-mamide (DMF), hexamethyl phosphoramide and especially mixtures thereof with l-methyl-2-pyrrolidone. For the highest heparin content materials a small amount of about 0.01% to 5% of a prim-ary or secondary amine such as dibutylamine in DMF is necessary to achieve complete solubility.
The block polymer forms by ionic reaction of the qua-ternized elastomer, (chloride counterion), with sodium heparin :i ,:, with elimination of sodium chloride. Hence, the amount of chloride after reaction is very low. The reaction is conducted simply by combining the elastomer with sodium heparin preferably as separate solutions in solvent, suitably in 50:50 by volume mixtures of methanol and wat~r.
Copolymers of the polyquaternary polyurethane and anionic polymer to which an anionic or cationic antimicrobial compound or dye group has been subsequently attached as herein-after described are conveniently represented by the structure:
..
~ 7 ~
10~i9394 _ ~
Z - - Rl - ZY - R -- Y
; The present invention relates to antimicrobial surgical aids, particularly sutures, that have present on the surface thereof a polymer coating, particularly on antimicrobial composi-tion that is not readily removed from the suture by leaching with water.
Germicidal sutures are described in the U.S. Patents No. 8~1,231, 1,741,893, and 2,751,910 and more recently in patents that have issued to Dr. Leonard D. Kurtz, i.e., U.S.
Patent No. 3,~42,003. South African Patent No. 724,131 describes a suture having long-lasting germicidal properties against both gram-negative and gram-positive bacteria due to the presence with-in the suture of an insoluble salt of a cation of a basic anti-biotic and an anion of an acid antibiotic, i.e., gentamycin oxa-cillinate. It is stated that such sutures, after being placed in mice for five days show no growth of organisms when removed and placed in a culture medium.
~, The Kliment et al British Patent 1,248,513 and the , Shepherd U.S. Patent 3,632,416 and U.S. 3,674,901 describe coated sutures that will accept medicinal agents. But, it is a disad-vantage of the suture coatings described that they have in~erior mechanical properties and are easily removed from the suture.
The suture of the present invention offers an advantage over those described in South African Patent No. 724,131 in that any anionic or cationic antimicrobial may be incorporated in the suture, and the incorporation may take place at the time of manufacture or at the time of use. Once incorporated in the suture, the antimicrobial will be retained by the suture strand over extended periods of use. Water, blood and tissue fluids slowly leach the antimicrobial compound out of the suture over a prolonged period of time.
The sutures of the present invention are any convention-al multifilament or monofilament suture material including for .
~0~39~
.
example, polyester, polypropylene, silk, cotton and linen which is coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer such as heparin. The coated suture is receptive to treatment with anionic or cationic antimicrobial compounds and/or anionic or cationic dyes. The antimicrobial treated suture is resis~ent to leaching and retains its antimicrobial properties in the pres-; ence of water or tissue fluid for a significant period of time to inhibit bacterial growth in and around the suture. The dyed sutures are useful for quick identification in surgical proce-dures where multiple sutures are employed.
The invention relates to an antimicrobial surgical aid the surface of which is coated with ~n ionic block elastomer of the formula:
Z - - Rl - ZY - R _y 12 ...x _ 3 4 R5 _ n wherein R is Cl-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, Rl is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y, n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic antimicrobial compound.
The preferred antimicrobial surgical aids of the pres-ent invention are suture strands coated with high-heparin content polyquaternary polyurethane elastomer and then treated with selected antimicrobials. The bonding of heparin to polymers has been reported by Yen & Rembaum, J. Biomed. Mater, Res. Symposium, Vol. 1 pp 83-97 (1971). Block copolymers of poly-quaternary ~ ;9394 polyure~hane and heparin containing from 5 to 20 percent of he-parin are described and claimed in U.S. Patent 3,755,218 where such copolymers are disclosed as having non-thrombogenic charac-teristics and suggested for use in coating surgical devices such as membranes, tubes, catheters, valves, prosethetic veins and the like where blood clotting is of g-eat concern. I have now found that these high-heparin content polyquaternary polyurethare elastomers are a useful substrate for retaining and slowly releasing selected antimicrobial compounds. While any of a variety of surgical aids may be rendered antimicrobial by the method of the present invention, the treatment of sutures is a particularly preferred embodiment of the present invention and the ensuing description will accordingly be directed primarily to sutures.
A preferred ionically bonded block elastomeric copo-lymer that functions as the coating material and the substrate for the antimicrobial compound or dye group in the present in ;~
vention is described in U.S. Patent 3,755,218. The copolymer formed between heparin and a polyquaternary polyurethane may be represented by the formula:
~ Z '----Rl--ZY~R ~ Y ~ .
R12 (I) ;~
/ ~ \ B-_ R3 R4 R5 n where R is Cl-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, Rl is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups and ZY is the urethane residue of the condensation of Z
and Y; n is an integer from 10 to 1,000; and B- is heparin. As used herein, lower~alkyl and alkylene radicals are those con-,. . -: ~
~1069394 taining from 1 to about ~ carbon atoms, and preferably from 1 to 4 carbon atoms.
The general reaction synthesis for the preparation of the polyquaternary polyurethane comprises reaction of a compound of the formula:
z-Rl-Z (II) or Z-Rl-Y (III) with a compound of the formula:
Y-R-Y or Z-RI-Y
12 (IV) lR2 (V) R3-N-R4 R3-~-R3 to form an intermediate non-charged or neutral poly-tertiary amino polymer of the formula:
_ _ z _--Rl--ZY-R ---_ y . IR2 (VI) R3 -N-R4 n where R, Rl, R2, R3 and R4 and n have the above-defined meanings.
The polymer is then reacted with a quaternizing reagent of the formula:
where A is an anion, suitably halo, to form a polymer having the structure:
Z- ~Rl--ZY--R ----y R2 (vII) N+ A-. _ 3 R4 R.5 _ n The materials for the monomeric materials of Formula I
and Formula II are preferably liquids of prepolymer length having a molecular weight above about 400 and below the range at which the prepolymer becomes excessively viscous or solid, suitably _ ~ _ 'I ~)fà9394 below 6,000 and preferably l,000 to 3,000. The group Rl may be an aromatic or aliphatic hydrocarbon, either saturated or un-saturated or may be a polyether, silicone (e.g., a siloxane), polyamide, polyurethane or other type of prepolymer.
The Z and Y groups are selected from condensation coreactants generally utilized in forming condensation resins such as isocyanate-hydroxyl (urethane) isocyanate-amine (urea), hydroxyl-carboxyl (polyester) amino-carboxyl (amide) and the like. Urethane linking reactants are preferred due to the ready availability of diverse polyisocyanate materials, the absence of elimination products and the ready ability to select and con- ;
trol the properties of the final prepolymer.
Examples of suitable monomeric diisocyanates include benzene-1,3-diisocyanate, hexane-1,6-diisocyanate, tolylene-2,4-diisocyanate (TDI), tolylene-2,3-diisocyanate, diphenylmethane-` 4,4-diisocyanate, naphthalene-1,5-diisocyanate, diphenyl 3,3'-dimethyl-4,4'-diisocyanate, diphenyl-3,3'-dimethoxy-4,4'-diiso-cyanate diethyl etner, 3 (diethylamino) pentane-1,5-diisocyanate, butane-l,4-diisocyanate, cyclohex-4-ene-1,2-diisocyanate, tolui-dine diisocyanate, isocyanate terminated prepolymers, polyaryl diisocyanates, and the like. Suitable commercially available higher molecu~ar weight liquid polyisocyanates are Adiprene L-lO0 (Trademark of DuPont), an isocyanate terminated polybutyl-ene oxide having a molecular weight of about 2,000 and Adiprene L-167 (Trademark of DuPont), an isocyanate terminated polybutyl-ene oxide having a molecular weight of about 1,350.
Terminally reactive liquid polymers, such as hydroxy terminated polybutadienes containing 20 to 500 or more carbon atoms or Bis-phenol A terminated liquid polysiloxanes can be converted to diisocyanates by reaction with a diisocyanate such as hexa-methylene diisocyanate. As the carbon chain length of the prepolymer increases, elastomeric properties are favored.
10~;939~
The Rl group in the monomeric compounds of Formulas III and IV may be aliphatic, aromatic or the various prepolymers discussed above. In the case of the use of a prepolymer diiso-cyanate the hydroxy amine material is suitably a compound of ; the formula:
OH(CH ) CH(CH ) (C12)m where R6 and R7 are lower alkyl, aryl such as phenyl, aralkyl such as benzyl or lower alkenyl, and each m is individually an integer from 0 to about 6 and m' is an integer of from 1 to about 6. Exemplary compounds are 3-dimethylamino-1,2,-propane diol, 4-diethylamino-1,3-butane diol 5-dimethylamino-1,4-hexane diol.
In the ~uaternizing reagent R5A, R5 may be hydrogen or lower alkyl, and A may be halo such as chloro, bromo or iodo, alkyl sulfate such as methyl sulfate, or alkyl iodide such as methyl iodide.
The polymerization reaction may be conducted in bulk or in the presenceof a solvent for the monomers and polymer pro-duct such as benzene. The reaction may be conducted at room temperature or at elevated temperature up to or above the reflux temperature. The quaternization reaction is conducted in the presence of a solventfor the tertiary amino polymer and for the resulting quaternary salt such as tetrahydrofuran, acetone, dioxane, dimethylformamide, diaminoheptane, or mixtures thereof.
The quaternized elastomeric polymer are further reacted with anionic polymers or salts thereof such as polystyrene sul-fonate, polyacrylates and the like and particularly with heparin or its alkali metal or ammonium salts to form viscoelastic ionically linked block polymeric salts of the formula:
1~939~
Z ~ R -ZY - R ~ Y
L R3 R~ R5 ~
wherein B- is an anionic polymer, preferably heparin, and R - R5, Z, Y and n are as defined above.
The heparin content æ the block polymer can be varied between 5% to about 20% by weight. Higher heparin content - materials can be prepared but are found to have a lower degree of elasticity. Lower heparin content materials are soluble in common organic solvents while materials containing above 15% - -; heparin are soluble in polar solvents such as THF, dimethylfor-mamide (DMF), hexamethyl phosphoramide and especially mixtures thereof with l-methyl-2-pyrrolidone. For the highest heparin content materials a small amount of about 0.01% to 5% of a prim-ary or secondary amine such as dibutylamine in DMF is necessary to achieve complete solubility.
The block polymer forms by ionic reaction of the qua-ternized elastomer, (chloride counterion), with sodium heparin :i ,:, with elimination of sodium chloride. Hence, the amount of chloride after reaction is very low. The reaction is conducted simply by combining the elastomer with sodium heparin preferably as separate solutions in solvent, suitably in 50:50 by volume mixtures of methanol and wat~r.
Copolymers of the polyquaternary polyurethane and anionic polymer to which an anionic or cationic antimicrobial compound or dye group has been subsequently attached as herein-after described are conveniently represented by the structure:
..
~ 7 ~
10~i9394 _ ~
Z - - Rl - ZY - R -- Y
2 ....... ..... X
/ N+ B-_ R3 R4 R5 _ n ; wherein X is said antimicrobial compound or dye group.
The attachment of the antimicrobial or dye group to the heparin elastomer is represented in the formula with a dotted line because thetrue mechanism of bonding is not known. While not wishing to be bound by theory, according to one possible mechanism the heparin elastomer may contain free positively charged nitrogen atoms and free negatively charged sulpho groups which are available for binding anionic (X-) or cationic (X+) antimicrobial or dye groups. Under another possible mechanism, the addition of the antimicrobial agent or dye group may result in dissocation of the heparin elastomer with precipitation and/or entrapment of the heparin-antimicrobial or heparin-dye complex within the polymer matrix. While either or both of these mechanisms may occur, or some other mechanism may be involved, knowledge of the true mechanism is not essential to understanding or operating the present invention.
; The polyquaternary polyurethane-heparin copolymer will retain basic antimicrobials such as gentamycin or benzethonium chloride and acid antibiotics such as thepenicillins. Other examples of suitable antimicrobials which are retained by the high-heparin content polyquaternary polyurethane elastomers and slowly released after implantation of the suture are the cephalo-sporins such as cephalolexin, cephaloglycin, cephaloridine, ceph-alothin; the 6-substituted penicillanic acids such as penicillins G, N and V, methicillin, oxacillin, and also vanco-mycin, neomycin, erythromycin, streptomycin, cycloserine, tetra-cycline, aureomycin, tetramycin (oxytetracycline)gentamycin, and . , :
. . .
~ti9~9~
polymyxin B. Particularly preferred is neomycin sulfate.
The base fiber to which the elastomeric heparin poly-mer coating is applied may be any non-absorbable suture material such as nylon, silk, polyester, and cotton or any absorbable suture material, such as catgut and homopolymers and copolymers of glycolide and lactide.
While any base fiber may be coated with the elastomeric heparin polymer, the adhesion of the coating to a fiber such as polypropylene is relatively poor, and the applications of such `
coated fibers are to be limited accordingly.
The elastomeric polymer is dissolved in a suitable solvent and applied to the suture material from solution. In a preferred method, the suture is immersed in a solution contain-ing from about 1.0 to about 50% by weight of the polymer, and preferably from about 3 to about 30 percent in dimethylformamide solvent. The suture is dried to remove the solvent and leave a uniform residual coating of elastomeric heparin polymer.
Successive coatings may be applied by reimmersing and reapplying the suture any number of times until the desired level of polymer addition is achieved. In general, from 0.1 to 25 percent of polymer by weight of the suture constitutes an effective range of polymer add-on. Greater or lesser amounts of polymer may of course be beneficially used although amounts in excess of 25 percent may result in stiffening of the suture and in some adhesion between adjacent strands when the suture is spooled.
The coated suture is capable of accepting a wide range of antimicrobials. The coated suture may be sterilized, pack-aged, and held in such neutral form until ready for use at which ; time a selected antimicrobial may be easily applied. Such a suture makes possible the selection of the most efrective anti-` microbial for use in a particular case.
Alternatively, the suture may be treated with a selected antimicrobial, sterilized and packaged and stored for later use.
In the event the selected antimicrobial is adversely affected by the suture sterilization technique the coated suture may be sterilized prior to the application of a sterile antimicrobial, and the treated suture packaged under antiseptic conditions.
Such mechanical procedures are conventional and well within the ability of those skilled in the art. Sterilization for example, may be by exposure to ethylene o~ide or cobalt 60 radiation or other conventional means.
The selected antimicrobial is conveniently applied to the coated suture from aqueous solution. The coated suture is simply immersed in the solution for a period of a few seconds to several minutes or longer, then removed a~d either dried or used "as is", without drying. The concentration of antimicrobial in the treating solution may vary according to solubility of parti-cular compounds but~concentrations in the range of from about 1.0 to L0 percent by weight are generally satisfactory although lesser or greater concentrations may be used if desired.
The elastomeric heparin polymer may also be applied to any prosthetic device useful in surgical applications where a surgical aid or support is required, i.e., heart valves, woven or extruded tubular structures having use in the repair of arteries, veins, ducts, asophagi; woven or knitted fabrics use-ful surgically in hernia repair and in supporting damaged liver, kidney, and other internal organs, pins, screws, reinforcing plates, and artificial tendons or cartilage material. Antimicro-bial compositions applied to the surface of surgical aids that have been so treated are retained by the elastomeric heparin poly-mer and slowly released. r Other surgical aids on which the elastomeric heparin polymer may also be used as a coating include bandages and other wound dressings designed for topical applications. Alternatively, ' ~ - 10 -, - , . .. .. . . . .... . . . .
1~16939~
the polymer may be cast a~ a thin polymeric film, sterilized, and packaged for use as a wound dressing. As in the case of sutures, the antimicrobial material may be incorporated in the elastomeric heparin polymer at the time of manufacture or at the time of use. In addition to the antimicrobial, a local anesthe-tic such as cinchocaine hydrochloride may also be applied to the surface of the elastomeric coating or film.
The polyquaternary polyurethane heparin polymer coated sutures are also receptive to anionic and cationic dyes and may accordingly be dyed a wide range of colors. The dyes may be applied alone or in conjunction with one or more antimicrobial compounds. The dyes are conveniently applied to the suture from aqueous solutions at ambient temperature by immersion, padding.
; spraying or the like.
The following examples are presented solely for the purpose of illustration. It is to be understood that many al-ternative, equivalent reactants and conditions may readily be substituted by those skilled in the art. Antimicrobial activity of the sutures of this invention were evaluated in vitro in accordance with the following test procedure:
Standard Testing Procedure for Assessing the In Vitro Efficacy of Anti _c obial Sutures Organisms: Bacillus subtilis ATCC 19659 Escherichia coli ATCC 10536 Pseudomonas aeruginosa ATCC 15442 Staphylococus aureus ATCC 6835 Media: Tryptic soy broth (Difco) + 0.4% Ion Agar 2 S
~ Procedure:
.'~
1. Plates of tryptic soy agar were streaked with the appropriate organism and incubated overnight at 37C. Cells were washed from the surface by means of glass beads and saline. The optical den-sity of each suspension was adjusted to 0.1.
~9~9~ ~
2. Tubes of tryptic soy broth + 0.4% Ion Agar 2 S were equili-brated to a temperature of 45 - 50C in a water bath. Ten per-cent (or 2.5 ml/25 ml tryptic soy broth + 0.4% Ion Agar 2 S) bovine serum and one percent (or 0.25 ml) of the adjusted bac-terial suspension were pipetted into the media and mixed by slow vortexing or by hand. Eight milliliters of this seeded media were pipetted per plate and allowed to cool.
/ N+ B-_ R3 R4 R5 _ n ; wherein X is said antimicrobial compound or dye group.
The attachment of the antimicrobial or dye group to the heparin elastomer is represented in the formula with a dotted line because thetrue mechanism of bonding is not known. While not wishing to be bound by theory, according to one possible mechanism the heparin elastomer may contain free positively charged nitrogen atoms and free negatively charged sulpho groups which are available for binding anionic (X-) or cationic (X+) antimicrobial or dye groups. Under another possible mechanism, the addition of the antimicrobial agent or dye group may result in dissocation of the heparin elastomer with precipitation and/or entrapment of the heparin-antimicrobial or heparin-dye complex within the polymer matrix. While either or both of these mechanisms may occur, or some other mechanism may be involved, knowledge of the true mechanism is not essential to understanding or operating the present invention.
; The polyquaternary polyurethane-heparin copolymer will retain basic antimicrobials such as gentamycin or benzethonium chloride and acid antibiotics such as thepenicillins. Other examples of suitable antimicrobials which are retained by the high-heparin content polyquaternary polyurethane elastomers and slowly released after implantation of the suture are the cephalo-sporins such as cephalolexin, cephaloglycin, cephaloridine, ceph-alothin; the 6-substituted penicillanic acids such as penicillins G, N and V, methicillin, oxacillin, and also vanco-mycin, neomycin, erythromycin, streptomycin, cycloserine, tetra-cycline, aureomycin, tetramycin (oxytetracycline)gentamycin, and . , :
. . .
~ti9~9~
polymyxin B. Particularly preferred is neomycin sulfate.
The base fiber to which the elastomeric heparin poly-mer coating is applied may be any non-absorbable suture material such as nylon, silk, polyester, and cotton or any absorbable suture material, such as catgut and homopolymers and copolymers of glycolide and lactide.
While any base fiber may be coated with the elastomeric heparin polymer, the adhesion of the coating to a fiber such as polypropylene is relatively poor, and the applications of such `
coated fibers are to be limited accordingly.
The elastomeric polymer is dissolved in a suitable solvent and applied to the suture material from solution. In a preferred method, the suture is immersed in a solution contain-ing from about 1.0 to about 50% by weight of the polymer, and preferably from about 3 to about 30 percent in dimethylformamide solvent. The suture is dried to remove the solvent and leave a uniform residual coating of elastomeric heparin polymer.
Successive coatings may be applied by reimmersing and reapplying the suture any number of times until the desired level of polymer addition is achieved. In general, from 0.1 to 25 percent of polymer by weight of the suture constitutes an effective range of polymer add-on. Greater or lesser amounts of polymer may of course be beneficially used although amounts in excess of 25 percent may result in stiffening of the suture and in some adhesion between adjacent strands when the suture is spooled.
The coated suture is capable of accepting a wide range of antimicrobials. The coated suture may be sterilized, pack-aged, and held in such neutral form until ready for use at which ; time a selected antimicrobial may be easily applied. Such a suture makes possible the selection of the most efrective anti-` microbial for use in a particular case.
Alternatively, the suture may be treated with a selected antimicrobial, sterilized and packaged and stored for later use.
In the event the selected antimicrobial is adversely affected by the suture sterilization technique the coated suture may be sterilized prior to the application of a sterile antimicrobial, and the treated suture packaged under antiseptic conditions.
Such mechanical procedures are conventional and well within the ability of those skilled in the art. Sterilization for example, may be by exposure to ethylene o~ide or cobalt 60 radiation or other conventional means.
The selected antimicrobial is conveniently applied to the coated suture from aqueous solution. The coated suture is simply immersed in the solution for a period of a few seconds to several minutes or longer, then removed a~d either dried or used "as is", without drying. The concentration of antimicrobial in the treating solution may vary according to solubility of parti-cular compounds but~concentrations in the range of from about 1.0 to L0 percent by weight are generally satisfactory although lesser or greater concentrations may be used if desired.
The elastomeric heparin polymer may also be applied to any prosthetic device useful in surgical applications where a surgical aid or support is required, i.e., heart valves, woven or extruded tubular structures having use in the repair of arteries, veins, ducts, asophagi; woven or knitted fabrics use-ful surgically in hernia repair and in supporting damaged liver, kidney, and other internal organs, pins, screws, reinforcing plates, and artificial tendons or cartilage material. Antimicro-bial compositions applied to the surface of surgical aids that have been so treated are retained by the elastomeric heparin poly-mer and slowly released. r Other surgical aids on which the elastomeric heparin polymer may also be used as a coating include bandages and other wound dressings designed for topical applications. Alternatively, ' ~ - 10 -, - , . .. .. . . . .... . . . .
1~16939~
the polymer may be cast a~ a thin polymeric film, sterilized, and packaged for use as a wound dressing. As in the case of sutures, the antimicrobial material may be incorporated in the elastomeric heparin polymer at the time of manufacture or at the time of use. In addition to the antimicrobial, a local anesthe-tic such as cinchocaine hydrochloride may also be applied to the surface of the elastomeric coating or film.
The polyquaternary polyurethane heparin polymer coated sutures are also receptive to anionic and cationic dyes and may accordingly be dyed a wide range of colors. The dyes may be applied alone or in conjunction with one or more antimicrobial compounds. The dyes are conveniently applied to the suture from aqueous solutions at ambient temperature by immersion, padding.
; spraying or the like.
The following examples are presented solely for the purpose of illustration. It is to be understood that many al-ternative, equivalent reactants and conditions may readily be substituted by those skilled in the art. Antimicrobial activity of the sutures of this invention were evaluated in vitro in accordance with the following test procedure:
Standard Testing Procedure for Assessing the In Vitro Efficacy of Anti _c obial Sutures Organisms: Bacillus subtilis ATCC 19659 Escherichia coli ATCC 10536 Pseudomonas aeruginosa ATCC 15442 Staphylococus aureus ATCC 6835 Media: Tryptic soy broth (Difco) + 0.4% Ion Agar 2 S
~ Procedure:
.'~
1. Plates of tryptic soy agar were streaked with the appropriate organism and incubated overnight at 37C. Cells were washed from the surface by means of glass beads and saline. The optical den-sity of each suspension was adjusted to 0.1.
~9~9~ ~
2. Tubes of tryptic soy broth + 0.4% Ion Agar 2 S were equili-brated to a temperature of 45 - 50C in a water bath. Ten per-cent (or 2.5 ml/25 ml tryptic soy broth + 0.4% Ion Agar 2 S) bovine serum and one percent (or 0.25 ml) of the adjusted bac-terial suspension were pipetted into the media and mixed by slow vortexing or by hand. Eight milliliters of this seeded media were pipetted per plate and allowed to cool.
3. 1.5 centimeter pieces of potential antimicrobial sutures were then placed on the cool agar and incubated 24 hours at 37C.
Each test was performed in triplicate. No more than four pieces of antimicrobial suture were positioned on each plate, equidis-tant from the edges and the center. After incubation, accurate zone measurements were obtained, using vernier calipers. Measure-ments were taken of the total zone width at right angles to the longitudinal axis of the suture and included the suture diameter.
, . .
Fifty grams of ADIPRENE L 167 ! a polybutylene oxide diisocyanate commercially available from E.I. DuPont de Nemours ; & Co., Inc., Wilmington, Delaware 19898, containing between 6.15 and 6.55 percent of available isocyanate) is dissolved in 500 ml.
ben~ene and reacted with 4.6 grams of vacuum distilled 3-methyl-amino-1,2-propane diol at refluxing temperature for 48 hours.
The reaction is followed by means of I.R. spectra. The disap-pearance of the OH peak at ~ = 3480 cm as well as the NCO ab-sorption peak at ~= 2280 cm indicates completion of the reac- .
tion. At the end of 48 hours, 300 ml. of benzene is distilled from the reaction flask and the residue freeze dried to remove all residual benzene. The yield of the condensation product is 56.2 grams.
~ i Thirty grams of the condensation product of Example 1 is dissolved in 200 ml. of tetrahydrofuran. A concentrated solu-~36~39~
tion of hydrochloric acid (8 grams of 37-33 percent HC1 by weight) is added corresponding to a 100 percent stoichiometric excess.
The solution is stirred at room temperature overnight and then precipitated with 1500 ml.of n-hexane. It is then washed thoroughly with water to remove unreacted HCl. The quaternized polymer is dried in vacuum at 50C. overnight.
Twenty-five grams of the quaternized polymer described in Example 2 above is dissolved in 250 ml. of methanol. Distilled water (150 mli) is added to this mixture slowly with stirring to form a homogeneous solution ~Solution A).
Five grams of sodium heparin is dissolved in 125 ml. of -distilled water. To this solution is added slowly with stirring 175 ml. of methanol to produce a homogeneous heparin solution -(Solution B). The polymer solution (Solution A) is added quickly to the heparin solution (Solution B) with vigorous stirring. The resulting precipitate is collected, washed with water, and vacuum dried at room temperature. The yield after drying is 6.2 grams.
The heparin content of this product is 16 percent by weight.
Sixty feet of a size 2/0 strand of polyester fiber ~ suture is treated on a laboratory coating machine with a solution ;~ of 0.5 parts by weight of the heparin polymer prepared in Example ~; 3 above in 15 parts by weight;of dimethyl-formamide. The coated suture strand, after drying, contains 7.2 percent by weight of polymer and has good handling and tie-down properties.
A portion of the coated suture material is immersed for 1 hour in a solution obtained by dissolving 2.5 parts strepto-mycin sulfate in 50 parts distilled water. The suture is then removed, placed in a flask, and extracted by agitating with distilled water as follows:
;93~
(i) 500 ml. distilled water for 15 minutes ~ Agitated (ii) 500 ml. distilled water for 15 minutes ~ by ~iii) 500 ml. distilled water for 15 minutes ) swirling (iv) 500 ml. distilled water overnight 17 hours (v) Rinsed briefly under running distilled water.
The suture is then dried, sterilized by cobalt-~0 radi-ation and tested for in vitro antimicrobial activity. For comparison, two control polyester fiber sutures were included.
One was not coated with the high-heparin elastomer, but other-wise treated in exactly the same way. The second control was apolyester fiber suture, coated with the high-heparin content elastomer of Example 3 without further treatment. The ta~le below sllmmarizes the results. Zones of inhibition are measured in centimeters.
B. E. Ps. S.
Suture Materialsubtilis coli ~eruginosa Aureus Suture coated with high-heparin elas- ~-tomer. Treated in 0.55 0.19 no 0.44 , 20 aqueous streptomycin zones sulfate. Extracted with distilled water as described above.
Suture uncoated con-trol Treated in Aqueous streptomycin sulfate. no no no no Extracted approx. 18 zones zones zones zones hours with distilled water.
30 Suture coated with high heparin elastomer. no no no no ~`, No further treatment. zones zones zones zones After seven-day implantation in rats, no significant ;
j ~
:~ differences in tissue reaction were seen in any of the above listed sutures.
The procedure of Example 4 is repeated substituting different anionic and cationic antimicrobial compounds for the streptomycin sulfate of Example 4. Examples 5-7 used the same - . . ~ - :: : .; ; - , .
coated suture as used in Example 4. Examples 8-12 used an iden-tical suture except for a ~lightly lower level of coating. The efficiency of the various antimicrobial compounds after water extraction is apparent from the following data.
.
;~
'.
~ .
'' .
' ., :
..
;
.
~."', .
`~''i .
;"'~ .
~6~3394 o O N
r~ . .. * ~C ~C *
. R U~~1~1 0 :~
H O
~0 . ~ r O O * * * * *
~ . . O
O 0~ O
N
~o ~
O O ~~ :
_ .1 ~oD
Ei ~
o . O * ~' * * *
,' _ ~31 0 o . a) u~
~) :' N VO
.'`,1 tO
,. U~ .000000 ~ O ~ 0~ ~ ~o oV
u~I`r~
.. . . ~ O~ ~ r m ~1 ~ o ~ o o ~ , Q
$
s-, ,a ~, o 5~ . .
Vrl O~1 . ~ ~
R~,Crl ~1 ~ ~S O
,~. O~1 u~ , u m ., ~ ~
.,~ ~ u ~ u ~ -h X ~I
U U U~ U
~' O ~ ~ ~ ~ ~1 ~ O
:~ OOO~XOO
', rl O
. Q U `
; ~ ~ X
.,1 ~U~ U
~ ~ ~ o~ oo oO oO o 0 3~`1` 1` `g ~9 ~) ~s) ~1 t) ~U
m E~ o r-l 11 tl r-l Q ~ ~-1 Ln ~ I` ~D ~ O ~ ~ Z;
x ~ ~ ~ ~ ~ ~
m ~ H
~;9399~
A sample of the coated suture treated with neomycin sulfate of Example 5 was subjected to a prolonged series of water extractions in 1.5 liter quantities of distilled water as follows:
9-24 hour extractions 1-120 hour extractions 3-168 hour extractions At the end of these extractions, the treated suture produced a zone of inhibition of 1.26 cm against Bacillus subti- ~;
lis. A similarly treated but uncoated control demonstrated no antimicrobial properties after an initial 24 hour extraction.
A series of tests were run using a modified extraction r technique on sutures treated with antimicrobia~s, some of which ; were more susceptible to water extraction than those of the pre-vious examples. In all of the following examples, the sutures ~ . , was a braided polyester size 2-0 which had been coated with `~ about 7% by weight of the heparin polymar according to the method of Example 4. The sutures were cobalt sterilized and then im-mersed in a 5% aqueous solution of the selected antimicrobials for one hour at room temperature. The treated sutures were evaluated for antimicrobial activity before extraction and after periods of 1, 2 and 4 hours extraction in distilled water. The following data were obtained.
1al~;~394 3 o, ~, .~ .
. ~ ~ ~
,~ o o~~ ~ ~ .,. ..
` 00~ ~ ~1 Q
I d' O O O 0 ~1 I O u I ~ rl , ~D~rl O
~:: ,Q ~ ~
~ ~
H ~1 ~I d'H 00 Q,a) t~
~1 ~ 1~ ~It` U~ a)E~ O
O ~ O O O O U O
~I O ~10 0 a~
~
o a) (~ :
N ~11~ rl O E~
:, _ ~1 d~ ~ ~ ~ N~) O
.' Ei ~t` ~ O ~1 , :, U ' ' ' '~ ~ ~ O f~
:; _ ~_1 o ~-1o ~-1o o o a ,., , ! ~
N
, ;, ~ QO ~ a) d O . .. .~ S o ~ S:~ I rl ~1 0 ,~ C
,:~',' O ~ fd `: ~ - ~D
~ :~ U (I)5~ ~
;1 ~, e~ ~ ~
O ~ ~
X ~q 3 ~
OC
,~ U ' ~;' U
," ~ o ~ U C O ~ ~ : -R ~ ,~ rl o C ~ ~ o ., O ~ ~)~1 ~ ~ (a ~ ~
.`, s~ ~ ~ ~ ~ C ~ -., o ~ V ~ ~ ~ ~ o ~ :
., ~1 u~ ~ U S~
e~ ~ ~ ~ x ~
.~1 C rl o ~ o ~ ~ O
~rl U ~ o o C~ U ~ ~ ~ U
~; ~ E~ X
O ~ q ~ c Q) O rl~rl O ~ ~ O
r U ~
~l ~ r~
X
., ~1 0 s ~l o Q
o u~~D t`oD~ O ~I C a) ~d ,~ ,~ N N a~ ~) U
X ~ ~ ~1 ~36939~
Healthy young adult Sprague-Dawley rats were anesthe-tized, hair was removed from their backs with clippers and the skin prepared for surgery. Under sterile conditions, a 6" strand of the suture material of Example 5 was inserted with a small hemostat through a 0.5 cm incision in the dorsal subcutis on the right side. An antimicrobial treated but uncoated control strand ~ ~ ;
was placed on the left side. The incisions were closed and the rats returned to their suitably identified cages.
At appropriate time intervals, animals were sacrificed with carbon dioxide, the dorsal skin dissected and the exposed sutures removed aseptically. With a separate set of dry, sterile forceps and scissors for each separate strand, the outermost ends -of the strand ~ca. 1/4") were cut off and discarded. The remain-ing strand was cut into 1.5 cm pieces and, without resteriliza-tion, tested for residual antimicrobial activity by the in vitro method described above using B. subtilis as the indicator organ-ism. The test results presented in the table below clearly indi-cate the long lasting antimicrobial effect obtained with the coated sutures of this invention.
'~' :
Zones of Inhibit ion (cm) Implantation Time Suture of Uncoated (Davs~ ~xam~le 13 Control , .
0 (non-implanted) 2.09 2.22 3 0.31 no zones -7 0.46 no zones 14 0.44 no zones 21 0.14 no zones 28 0.04 no zones 9399t Braided nylon suture (size 2/0, undyed, not waxed) was coated with the heparin polyquaternary polyurethane elastomer as described in Example 4. After three passes through the coat-ing apparatus, the polymer add-on was found to be 8.01% based on weight of suture.
A 20 cm length of the coated nylon suture was soaked in 5% w/v neomycin sulphate solution for one hour at room temp-erature. After removal, the strand was washed in three separate 500 ml quantities of distilled water, 15 minutes in each wash , and then allowed to soak in 500 ml distilled water overnight.
The strand was then held under running distilled water for several seconds and dried at room temperature.
- Portions of the suture were then tested for residual '~ antimicrobial activity using B. subtilis as the test organism.
The mean of zones of inhibition was 1.44 cm. For comparison, a normal uncoated sample of nylon suture was soaked in neomycin ~; ,sulphate solution and then washed with water under exactly the same conditions as were used for the coated suture. This con-20 trol suture gave no zones of inhibition against the test organ-sm.
Braided silk suture (size 2/0 ~ undyed, not waxed) was treated with two coats of polymer solution, in a similar way to the procedure in Example 23. Polymer add-on was 2. 83% based on suture weight. Treatment in 5% neomycin sulphate solution followed by water extraction was carried out exactly as described in Example 23. Mean zone of inhibition against the test organ-ism B. subtilis was found to be 2. 06 cm.
_ . .
For comparison, ~ control silk suture without polymer coating, but otherwise similarly treated in neomycin sulphate solution followed by water extraction was found to give a mean ~ 20 --399~
zone of inhibition of 2.09 cm.
One gram of the heparin elastomer described in Example 3 is dissolved in 20 mL of dimethylformamide, 2 ml. of dibutyl-` amine, and 1 ml. of hexamethylphosphoramide, and cast as a thin film on a glass surface. The solvent is removed at 100C. in an oven and the film peeled away from the smooth glass surface. The film is soaked in an aqueous solution (4 percent by weight3 of tetracycline hydrochloride, air dried at room temperature, pack-;~ 10 aged and sterilized with cobalt-60 radiation. The thin films so obtained are useful for dressing skin wounds and burns.
; Braided polyester suture (size 2/0 white) was coated with heparin polymer as described in Example 4. The coated suture was sterilized by cobalt-60 in a conventional manner, and :
portions of the coated fiber were immersed in various dye solu-tions described below. A section of uncoated suture was included in each dye test as a control. Samples were removed from the dye bath, rinsed and evaluated for color. The following results were obtained.
Coated Uncoated Dye Solution Suture Control Rhodamine B (0.1 gm in 20 ml Deep Faintly tinged distilled water) pink with pink Bromothymol Blue (0.1 gm in 20 ml distilled water) Yellow Colorless Methylene Blue (0.1 gm in Dark Faintly tinged 20 ml distilled water) blue with blue Eriochrome Black T (0.1 gm Reddish in 20 ml distilled water) brown Colorless Bromocresol Green (0.1 gm in 20 ml distilled water insol.
residue filtered off~ Green Colorless 39~
Azure A (0.1 gm in 20 ml Deep Faintly tinged distilled water, insol. violet with blue residue filtered off) Quinizarin Sulphonic Acid Orange Colorless (0.1 gm in 20 ml distilled brown water, 10 drops 0.1 NaOH
solution added, insol.
residue filtered off) ; Thymol Blue (0.1 gm in Yellow Colorless ; 10 20 ml distilled water, 10 drops of 0.lN ~aOH
solution added, insol.
residue filtered off) Pararosaniline Hydro- Deep Faintly tinged chloride (0.1 gm in 20 violet with blue ml distilled water, 10 drops of 0.lN NaOH solu-' tion added, insol. resi-due filtered off) The following dyes were evaluated in a like manner. In all cases, the fibers coated in accordance with the instant in-vention were colored to a pale to medium shade, while the un-coated fibers showed no appreciable coloration: phenol red, uranine, parazylenol blue, haematein, methyl orange, methyl red, disodium salt of phenolphthalein, and bromopheno~ blue.
While the foregoing examples have described a preferred embodiment of the present invention wherein the suture coating comprised a copolymer of polyquaternary polyurethanes and hepar-in, these examples are for purposes of illustration only and are not limiting of the invention. Numerous substitutions, modifications and alternatives in polymer compositions, antimi-39~
crobial compounds and dye compounds will be apparent to thoseskilled in the art and may be employed without departing from the scope of the invention described in the following claims.
., . ..
: ' "~
,.~
~' .
, .
~,
Each test was performed in triplicate. No more than four pieces of antimicrobial suture were positioned on each plate, equidis-tant from the edges and the center. After incubation, accurate zone measurements were obtained, using vernier calipers. Measure-ments were taken of the total zone width at right angles to the longitudinal axis of the suture and included the suture diameter.
, . .
Fifty grams of ADIPRENE L 167 ! a polybutylene oxide diisocyanate commercially available from E.I. DuPont de Nemours ; & Co., Inc., Wilmington, Delaware 19898, containing between 6.15 and 6.55 percent of available isocyanate) is dissolved in 500 ml.
ben~ene and reacted with 4.6 grams of vacuum distilled 3-methyl-amino-1,2-propane diol at refluxing temperature for 48 hours.
The reaction is followed by means of I.R. spectra. The disap-pearance of the OH peak at ~ = 3480 cm as well as the NCO ab-sorption peak at ~= 2280 cm indicates completion of the reac- .
tion. At the end of 48 hours, 300 ml. of benzene is distilled from the reaction flask and the residue freeze dried to remove all residual benzene. The yield of the condensation product is 56.2 grams.
~ i Thirty grams of the condensation product of Example 1 is dissolved in 200 ml. of tetrahydrofuran. A concentrated solu-~36~39~
tion of hydrochloric acid (8 grams of 37-33 percent HC1 by weight) is added corresponding to a 100 percent stoichiometric excess.
The solution is stirred at room temperature overnight and then precipitated with 1500 ml.of n-hexane. It is then washed thoroughly with water to remove unreacted HCl. The quaternized polymer is dried in vacuum at 50C. overnight.
Twenty-five grams of the quaternized polymer described in Example 2 above is dissolved in 250 ml. of methanol. Distilled water (150 mli) is added to this mixture slowly with stirring to form a homogeneous solution ~Solution A).
Five grams of sodium heparin is dissolved in 125 ml. of -distilled water. To this solution is added slowly with stirring 175 ml. of methanol to produce a homogeneous heparin solution -(Solution B). The polymer solution (Solution A) is added quickly to the heparin solution (Solution B) with vigorous stirring. The resulting precipitate is collected, washed with water, and vacuum dried at room temperature. The yield after drying is 6.2 grams.
The heparin content of this product is 16 percent by weight.
Sixty feet of a size 2/0 strand of polyester fiber ~ suture is treated on a laboratory coating machine with a solution ;~ of 0.5 parts by weight of the heparin polymer prepared in Example ~; 3 above in 15 parts by weight;of dimethyl-formamide. The coated suture strand, after drying, contains 7.2 percent by weight of polymer and has good handling and tie-down properties.
A portion of the coated suture material is immersed for 1 hour in a solution obtained by dissolving 2.5 parts strepto-mycin sulfate in 50 parts distilled water. The suture is then removed, placed in a flask, and extracted by agitating with distilled water as follows:
;93~
(i) 500 ml. distilled water for 15 minutes ~ Agitated (ii) 500 ml. distilled water for 15 minutes ~ by ~iii) 500 ml. distilled water for 15 minutes ) swirling (iv) 500 ml. distilled water overnight 17 hours (v) Rinsed briefly under running distilled water.
The suture is then dried, sterilized by cobalt-~0 radi-ation and tested for in vitro antimicrobial activity. For comparison, two control polyester fiber sutures were included.
One was not coated with the high-heparin elastomer, but other-wise treated in exactly the same way. The second control was apolyester fiber suture, coated with the high-heparin content elastomer of Example 3 without further treatment. The ta~le below sllmmarizes the results. Zones of inhibition are measured in centimeters.
B. E. Ps. S.
Suture Materialsubtilis coli ~eruginosa Aureus Suture coated with high-heparin elas- ~-tomer. Treated in 0.55 0.19 no 0.44 , 20 aqueous streptomycin zones sulfate. Extracted with distilled water as described above.
Suture uncoated con-trol Treated in Aqueous streptomycin sulfate. no no no no Extracted approx. 18 zones zones zones zones hours with distilled water.
30 Suture coated with high heparin elastomer. no no no no ~`, No further treatment. zones zones zones zones After seven-day implantation in rats, no significant ;
j ~
:~ differences in tissue reaction were seen in any of the above listed sutures.
The procedure of Example 4 is repeated substituting different anionic and cationic antimicrobial compounds for the streptomycin sulfate of Example 4. Examples 5-7 used the same - . . ~ - :: : .; ; - , .
coated suture as used in Example 4. Examples 8-12 used an iden-tical suture except for a ~lightly lower level of coating. The efficiency of the various antimicrobial compounds after water extraction is apparent from the following data.
.
;~
'.
~ .
'' .
' ., :
..
;
.
~."', .
`~''i .
;"'~ .
~6~3394 o O N
r~ . .. * ~C ~C *
. R U~~1~1 0 :~
H O
~0 . ~ r O O * * * * *
~ . . O
O 0~ O
N
~o ~
O O ~~ :
_ .1 ~oD
Ei ~
o . O * ~' * * *
,' _ ~31 0 o . a) u~
~) :' N VO
.'`,1 tO
,. U~ .000000 ~ O ~ 0~ ~ ~o oV
u~I`r~
.. . . ~ O~ ~ r m ~1 ~ o ~ o o ~ , Q
$
s-, ,a ~, o 5~ . .
Vrl O~1 . ~ ~
R~,Crl ~1 ~ ~S O
,~. O~1 u~ , u m ., ~ ~
.,~ ~ u ~ u ~ -h X ~I
U U U~ U
~' O ~ ~ ~ ~ ~1 ~ O
:~ OOO~XOO
', rl O
. Q U `
; ~ ~ X
.,1 ~U~ U
~ ~ ~ o~ oo oO oO o 0 3~`1` 1` `g ~9 ~) ~s) ~1 t) ~U
m E~ o r-l 11 tl r-l Q ~ ~-1 Ln ~ I` ~D ~ O ~ ~ Z;
x ~ ~ ~ ~ ~ ~
m ~ H
~;9399~
A sample of the coated suture treated with neomycin sulfate of Example 5 was subjected to a prolonged series of water extractions in 1.5 liter quantities of distilled water as follows:
9-24 hour extractions 1-120 hour extractions 3-168 hour extractions At the end of these extractions, the treated suture produced a zone of inhibition of 1.26 cm against Bacillus subti- ~;
lis. A similarly treated but uncoated control demonstrated no antimicrobial properties after an initial 24 hour extraction.
A series of tests were run using a modified extraction r technique on sutures treated with antimicrobia~s, some of which ; were more susceptible to water extraction than those of the pre-vious examples. In all of the following examples, the sutures ~ . , was a braided polyester size 2-0 which had been coated with `~ about 7% by weight of the heparin polymar according to the method of Example 4. The sutures were cobalt sterilized and then im-mersed in a 5% aqueous solution of the selected antimicrobials for one hour at room temperature. The treated sutures were evaluated for antimicrobial activity before extraction and after periods of 1, 2 and 4 hours extraction in distilled water. The following data were obtained.
1al~;~394 3 o, ~, .~ .
. ~ ~ ~
,~ o o~~ ~ ~ .,. ..
` 00~ ~ ~1 Q
I d' O O O 0 ~1 I O u I ~ rl , ~D~rl O
~:: ,Q ~ ~
~ ~
H ~1 ~I d'H 00 Q,a) t~
~1 ~ 1~ ~It` U~ a)E~ O
O ~ O O O O U O
~I O ~10 0 a~
~
o a) (~ :
N ~11~ rl O E~
:, _ ~1 d~ ~ ~ ~ N~) O
.' Ei ~t` ~ O ~1 , :, U ' ' ' '~ ~ ~ O f~
:; _ ~_1 o ~-1o ~-1o o o a ,., , ! ~
N
, ;, ~ QO ~ a) d O . .. .~ S o ~ S:~ I rl ~1 0 ,~ C
,:~',' O ~ fd `: ~ - ~D
~ :~ U (I)5~ ~
;1 ~, e~ ~ ~
O ~ ~
X ~q 3 ~
OC
,~ U ' ~;' U
," ~ o ~ U C O ~ ~ : -R ~ ,~ rl o C ~ ~ o ., O ~ ~)~1 ~ ~ (a ~ ~
.`, s~ ~ ~ ~ ~ C ~ -., o ~ V ~ ~ ~ ~ o ~ :
., ~1 u~ ~ U S~
e~ ~ ~ ~ x ~
.~1 C rl o ~ o ~ ~ O
~rl U ~ o o C~ U ~ ~ ~ U
~; ~ E~ X
O ~ q ~ c Q) O rl~rl O ~ ~ O
r U ~
~l ~ r~
X
., ~1 0 s ~l o Q
o u~~D t`oD~ O ~I C a) ~d ,~ ,~ N N a~ ~) U
X ~ ~ ~1 ~36939~
Healthy young adult Sprague-Dawley rats were anesthe-tized, hair was removed from their backs with clippers and the skin prepared for surgery. Under sterile conditions, a 6" strand of the suture material of Example 5 was inserted with a small hemostat through a 0.5 cm incision in the dorsal subcutis on the right side. An antimicrobial treated but uncoated control strand ~ ~ ;
was placed on the left side. The incisions were closed and the rats returned to their suitably identified cages.
At appropriate time intervals, animals were sacrificed with carbon dioxide, the dorsal skin dissected and the exposed sutures removed aseptically. With a separate set of dry, sterile forceps and scissors for each separate strand, the outermost ends -of the strand ~ca. 1/4") were cut off and discarded. The remain-ing strand was cut into 1.5 cm pieces and, without resteriliza-tion, tested for residual antimicrobial activity by the in vitro method described above using B. subtilis as the indicator organ-ism. The test results presented in the table below clearly indi-cate the long lasting antimicrobial effect obtained with the coated sutures of this invention.
'~' :
Zones of Inhibit ion (cm) Implantation Time Suture of Uncoated (Davs~ ~xam~le 13 Control , .
0 (non-implanted) 2.09 2.22 3 0.31 no zones -7 0.46 no zones 14 0.44 no zones 21 0.14 no zones 28 0.04 no zones 9399t Braided nylon suture (size 2/0, undyed, not waxed) was coated with the heparin polyquaternary polyurethane elastomer as described in Example 4. After three passes through the coat-ing apparatus, the polymer add-on was found to be 8.01% based on weight of suture.
A 20 cm length of the coated nylon suture was soaked in 5% w/v neomycin sulphate solution for one hour at room temp-erature. After removal, the strand was washed in three separate 500 ml quantities of distilled water, 15 minutes in each wash , and then allowed to soak in 500 ml distilled water overnight.
The strand was then held under running distilled water for several seconds and dried at room temperature.
- Portions of the suture were then tested for residual '~ antimicrobial activity using B. subtilis as the test organism.
The mean of zones of inhibition was 1.44 cm. For comparison, a normal uncoated sample of nylon suture was soaked in neomycin ~; ,sulphate solution and then washed with water under exactly the same conditions as were used for the coated suture. This con-20 trol suture gave no zones of inhibition against the test organ-sm.
Braided silk suture (size 2/0 ~ undyed, not waxed) was treated with two coats of polymer solution, in a similar way to the procedure in Example 23. Polymer add-on was 2. 83% based on suture weight. Treatment in 5% neomycin sulphate solution followed by water extraction was carried out exactly as described in Example 23. Mean zone of inhibition against the test organ-ism B. subtilis was found to be 2. 06 cm.
_ . .
For comparison, ~ control silk suture without polymer coating, but otherwise similarly treated in neomycin sulphate solution followed by water extraction was found to give a mean ~ 20 --399~
zone of inhibition of 2.09 cm.
One gram of the heparin elastomer described in Example 3 is dissolved in 20 mL of dimethylformamide, 2 ml. of dibutyl-` amine, and 1 ml. of hexamethylphosphoramide, and cast as a thin film on a glass surface. The solvent is removed at 100C. in an oven and the film peeled away from the smooth glass surface. The film is soaked in an aqueous solution (4 percent by weight3 of tetracycline hydrochloride, air dried at room temperature, pack-;~ 10 aged and sterilized with cobalt-60 radiation. The thin films so obtained are useful for dressing skin wounds and burns.
; Braided polyester suture (size 2/0 white) was coated with heparin polymer as described in Example 4. The coated suture was sterilized by cobalt-60 in a conventional manner, and :
portions of the coated fiber were immersed in various dye solu-tions described below. A section of uncoated suture was included in each dye test as a control. Samples were removed from the dye bath, rinsed and evaluated for color. The following results were obtained.
Coated Uncoated Dye Solution Suture Control Rhodamine B (0.1 gm in 20 ml Deep Faintly tinged distilled water) pink with pink Bromothymol Blue (0.1 gm in 20 ml distilled water) Yellow Colorless Methylene Blue (0.1 gm in Dark Faintly tinged 20 ml distilled water) blue with blue Eriochrome Black T (0.1 gm Reddish in 20 ml distilled water) brown Colorless Bromocresol Green (0.1 gm in 20 ml distilled water insol.
residue filtered off~ Green Colorless 39~
Azure A (0.1 gm in 20 ml Deep Faintly tinged distilled water, insol. violet with blue residue filtered off) Quinizarin Sulphonic Acid Orange Colorless (0.1 gm in 20 ml distilled brown water, 10 drops 0.1 NaOH
solution added, insol.
residue filtered off) ; Thymol Blue (0.1 gm in Yellow Colorless ; 10 20 ml distilled water, 10 drops of 0.lN ~aOH
solution added, insol.
residue filtered off) Pararosaniline Hydro- Deep Faintly tinged chloride (0.1 gm in 20 violet with blue ml distilled water, 10 drops of 0.lN NaOH solu-' tion added, insol. resi-due filtered off) The following dyes were evaluated in a like manner. In all cases, the fibers coated in accordance with the instant in-vention were colored to a pale to medium shade, while the un-coated fibers showed no appreciable coloration: phenol red, uranine, parazylenol blue, haematein, methyl orange, methyl red, disodium salt of phenolphthalein, and bromopheno~ blue.
While the foregoing examples have described a preferred embodiment of the present invention wherein the suture coating comprised a copolymer of polyquaternary polyurethanes and hepar-in, these examples are for purposes of illustration only and are not limiting of the invention. Numerous substitutions, modifications and alternatives in polymer compositions, antimi-39~
crobial compounds and dye compounds will be apparent to thoseskilled in the art and may be employed without departing from the scope of the invention described in the following claims.
., . ..
: ' "~
,.~
~' .
, .
~,
Claims (29)
1. An antimicrobial surgical aid, the surface of which is coated with an ionic block elastomer of the formula:
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic antimicrobial compound.
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic antimicrobial compound.
2. A surgical aid of claim 1 wherein the anionic polymer is selected from the group consisting of polystyrene sulfonate, polyacrylate and heparin.
3. A surgical aid of claim 1 wherein the antimicrobial compound is selected from the group consisting of neomycin sul-fate, tetracycline hydrochloride, potassium penicillin, strepto-mycin sulfate, gentamycin sulfate, oxtetracycline dihydrate, polymixing B sulfate, sodium cephalothin, rifamycin, benzethoni-um chloride, cephaloridine, sodium oxacillin, dihydrostrepto-mycin sulfate, and disodium carbenicillin.
4. A surgical aid of claim 3 wherein the anionic polymer is heparin.
5. A surgical aid of claim 1 which is a suture.
6. A surgical aid of claim 1 which is a wound dressing.
7. A surgical aid of claim 1 which is a fabric.
8. A surgical aid of claim 1 which is a prosthetic device.
9. A suture of claim 5 wherein B- is heparin and X is neomycin sulfate.
10. A colored surgical aid, the surface of which is coated with an ionic block elastomer of the formula:
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, and R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid prepolymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide; Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic dye group.
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, and R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid prepolymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide; Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, B- is an anionic polymer and X is an anionic or cationic dye group.
11. A surgical aid of claim 10 wherein the anionic polymer is selected from the group consisting of polystyrene sulfonate, polyacrylate and heparin.
12. A surgical aid of claim 10 which is a suture.
13. A surgical aid of claim 10 which is a wound dressing.
14. A surgical aid of claim 10 which is a fabric.
15. A suture of claim 12 wherein B- is heparin.
16. A sterile surgical suture, the surface of which is coated with an ionic block elastomer of the formula:
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, and B- is an anionic poly-mer.
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y; n is an integer from 10 to 1,000, and B- is an anionic poly-mer.
17. A surgical suture of claim 16 wherein the anionic polymer is selected from the group consisting of polystyrene sulfonate, polyacrylates, heparin.
18. A surgical suture of claim 16 wherein the anionic polymer is heparin.
19. A method of preparing an antimicrobial surgical aid comprising the steps of contacting the surface of a surgical aid with a solution of an ionic block elastomer of the formula:
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y, n is an integer from 10 to 1,000 and B- is an anionic polymer, drying said surgical aid to leave a residual coating of said ionic block elastomer thereon, and thereafter contacting said coated surgical aid with an anionic or cationic antimicrobial compound.
wherein R is C1-15 alkylene, R2 is lower alkylene, R3, R4 and R5 are selected from hydrogen and lower alkyl, R1 is a liquid pre-polymer having a molecular weight from 1,000 to 3,000 selected from the class consisting of polyether, silicone, polyurethane, and polyamide, Z and Y are selected from hydroxyl and isocyanate groups, ZY is the urethane residue of the condensation of Z and Y, n is an integer from 10 to 1,000 and B- is an anionic polymer, drying said surgical aid to leave a residual coating of said ionic block elastomer thereon, and thereafter contacting said coated surgical aid with an anionic or cationic antimicrobial compound.
20. A method of claim 19 wherein the anionic polymer is selected from the group consisting of polystyrene sulfonate, polyacrylates, heparin.
21. A method of claim 19 wherein said solution of ionic block elastomer comprises an organic solvent.
22. A method of claim 21 wherein said organic solvent com-prises dimethylformamide.
23. A method of claim 19 wherein said coated surgical aid is contacted with an aqueous solution of said antimicrobial com-pound.
24. A method of claim 19 wherein said anionic polymer is heparin.
25. A method of claim 24 wherein said antimicrobial com-pound is neomycin sulfate.
26. A method of claim 25 wherein said surgical aid is a suture.
27. A method of claim 25 wherein said surgical aid is a wound dressing.
28. A method of claim 25 wherein said surgical aid is a fabric.
29. A method of claim 25 wherein said surgical aid is a prosthetic device.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA238,786A CA1069394A (en) | 1975-10-31 | 1975-10-31 | Antimicrobial sutures |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA238,786A CA1069394A (en) | 1975-10-31 | 1975-10-31 | Antimicrobial sutures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1069394A true CA1069394A (en) | 1980-01-08 |
Family
ID=4104416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA238,786A Expired CA1069394A (en) | 1975-10-31 | 1975-10-31 | Antimicrobial sutures |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1069394A (en) |
-
1975
- 1975-10-31 CA CA238,786A patent/CA1069394A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3987797A (en) | Antimicrobial sutures | |
| CA1074230A (en) | Antimicrobial sutures | |
| US4542012A (en) | Film-forming composition containing an antimicrobial agent and methods | |
| AU2007207708B2 (en) | Non-leaching surface-active film compositions for microbial adhesion prevention | |
| US20110200655A1 (en) | Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic | |
| EP0328421B1 (en) | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same | |
| Grapski et al. | Synthesis and characterization of non-leaching biocidal polyurethanes | |
| AU768960B2 (en) | Infection resistant polymers, their preparation and uses | |
| US5169720A (en) | Protein non-adsorptive polyurea-urethane polymer coated devices | |
| JP2004511582A (en) | Biocidal polyurethane compositions and methods of use | |
| CN112500772A (en) | Betaine cation waterborne polyurethane antibacterial coating and preparation method thereof | |
| AU2007331144A1 (en) | Skin coating with microbial indicator | |
| EP0335308B1 (en) | Protein non-adsorptive polyurea-urethane polymer coated devices | |
| EP0100591B1 (en) | Film-forming composition containing an antimicrobial agent and methods | |
| CA1069394A (en) | Antimicrobial sutures | |
| US20010049422A1 (en) | Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology | |
| CN118307983A (en) | Antibacterial polyurethane and preparation method and application thereof | |
| DE2555624A1 (en) | Coating auxiliary surgical materials - pref sutures with ionically bonded elastomeric block copolymers retaining anti-microbial cpds or dyes | |
| AU2013245551A1 (en) | Non-leaching surface-active film compositions for microbial adhesion prevention | |
| GB1500409A (en) | Coated sutures | |
| EP1791505A1 (en) | Splinting orthopedic and rehabilitative product | |
| AU2007231679A1 (en) | Antimicrobial medical devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |